Lupin Share Price

Lupin Share Price

NSE: LUPIN | BSE: 500257

55% Buy

₹2,086.30

+₹14.90 (0.72%) Last updated on 15 May, 2025 | 09:25 IST
Market cap
Market Cap Switch₹94,264 Crs
Open
₹2,100.00
Prev. Close
₹2,071.40
Circuit range
₹2,278.50 - ₹1,864.30
Day range
₹2,063.80 - ₹2,118.90
Year range
₹1,493.30 - ₹2,402.90
Volume
5,07,136
Avg. traded
₹2,090.53
Revenue (12m)
₹22,002 Crs

About Lupin

Lupin Limited is an Indian multinational pharmaceutical company. It is one of the largest generic medicine manufacturers globally with its footprint in over 100 countries.

Headquartered in Mumbai, Lupin has a diverse portfolio of more than 1,000 products. The pharma company is among the leaders in business segments like generics, Active Pharmaceutical Ingredients (API), speciality and biologics.

Founded in 1968 by Dr. Desh Bandhu Gupta, a professor of Chemistry, Lupin was incorporated in 1972 and started its business as a vitamin manufacturer. It soon bagged a huge order for supplying iron and folic acid tablets from the central government for the mother and child healthcare programmes.

In 1979, the company commissioned its maiden formulation plant and research and development centre in Aurangabad, Maharashtra. Later, it extended operations beyond India’s borders by establishing Lupin Chemicals (Thailand) through a joint venture in 1989. Around the same time, Lupin obtained United States Food and Drug Agency (USFDA) nod for the Ankleshwar and Mandideep plants.

In their bid to tap the market, Lupin Laboratories Ltd and Lupin Chemicals Ltd floated IPOs successfully in 1993 and were enlisted in the stock exchanges. However, within eight years, both the companies were amalgamated to form the new entity, Lupin Ltd.

In 2003, the company set up Lupin Pharmaceuticals (US) for trading and marketing of drugs in the United States. Within two years the company began its generic medicine business in the country.

2007 was a landmark year for the company, as Lupin announced its maiden issue of $100 million worth Foreign Currency Convertible Bonds (FCCB), and was listed on the Singapore Stock Exchange. Lupin also acquired Japan's Kyowa Pharmaceutical Industry Co, which became its subsidiary.

In the next few years, Lupin acquired or bought partial stakes in several pharmaceutical companies abroad, including South Africa’s Pharma Dynamics, and Generic Health Ltd in Australia.

With its business valuation consistently going up, Lupin found a place in the Nifty 50 index in 2012.

In 2019, Lupin entered into a definitive agreement with Unison - the leading private equity fund in Japan - for the sale of its entire stake in Kyowa Pharmaceutical Industry Co Ltd.

Lupin Limited’s market capitalisation stood at more than ₹62,400 crore as of January 2, 2023. Lupin share price has gone up over 36% in the last three years.

Business operations

Lupin owns and operates 12 manufacturing plants in India at Aurangabad, Ankleshwar, Mandideep, Pune, Tarapur, Goa, Jammu, Vadodara, Indore, Nagpur, Visakhapatnam and Sikkim. It has three manufacturing units abroad in Mexico, Brazil and the US.

It has expanded its business operations across the US, Latin America, Asia Pacific, Europe, the Middle East and Africa. The pharma company is the world’s largest supplier of first-line anti-TB drugs. It’s also the 10th largest generic pharma company globally.

Notwithstanding pricing issues in the US, Lupin recorded $632 million in sales in FY23 there, and continues to be the third-largest pharmaceutical player by prescriptions in the country.

Financial highlights

Total revenue from operations increased by 1.43% to ₹16,641.66 crore in FY23 from ₹16,405.48 crore in FY22. Consolidated EBITDA (earnings before interest, taxes, depreciation,and amortisation) dropped by 18.88% to ₹1,871.5 crore in FY23 from ₹2307.3 crore in FY22. The company reported consolidated profit after tax (PAT) of ₹430 crore in FY23, compared to a loss of ₹1,528 crore in FY22. The company made a total capital expenditure of ₹64,128.8 crore in FY23. The company's earnings per share (EPS) increased to ₹9.46 in FY23 as against ₹(-33.65) recorded in FY22.

Lupin Share Price Chart

Please wait...
  • Fundamentals
  • Events
  • More
  • F&O (Option chain)
  • News

Lupin Key Indicators

P/E ratio
32.92
P/B ratio
5.78
ROE
12%
ROCE
14.33%
Dividend yield
0.38%
Debt/Equity ratio
EPS
51.04

Investment Checklist: (4/6)

passed

Equity returns

not passed

Dividend returns

passed

Safety factor

NA

Growth factor

passed

Debt vs Equity

passed

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst Ratings:

Buy

Buy

55%

Hold

32%

Sell

13%

This analysis is based on the reviews of 31 experts in the last 7 days

Lupin Financial Ratios

  • Profitability

  • Operational

  • Valuation

Operating profit margin

24.2%

Net profit margin

15.79%

ROE

12%

ROA

9.77%

ROCE

14.33%

Lupin Shareholder returns

1 day
+1.21%
1 week
+0.75%
1 month
+4.83%
3 months
+0.45%
1 year
+22.26%
3 years
+196.46%
5 years
+145.98%

Revenue Statement

All values are in ₹ Crores (Cr)
RevenueNo Sort
Operating ProfitNo Sort
Net ProfitNo Sort
Mar-24
20,010.82
3,930.69
1,935.57
Mar-23
16,641.66
1,871.48
447.69
Mar-22
16,405.48
428.91
-1,509.36
Mar-21
15,162.96
2,703.17
1,227.93

Cash Flow

All values are in ₹ Crores (Cr)
OperatingNo Sort
InvestingNo Sort
FinancingNo Sort
Mar-24
3,648.36
-1,712.2
-2184.21
Mar-23
1,897.24
-1,286.77
-337.25
Mar-22
367.31
1,292.23
-1572.32
Mar-21
1,821.76
-1,239.58
-1885.27

Balance Sheet

All values are in ₹ Crores (Cr)
Total AssetNo Sort
Total LiabilityNo Sort
Mar-24
23,694.65
9,321.20
Mar-23
22,800.28
10,257.46
Mar-22
21,651.49
9,429.51
Mar-21
23,430.23
9,572.12

Lupin Share Price History

DayOpenCloseChange %
14-May-25
₹2,066.20
₹2,071.40
+0.34%
13-May-25
₹2,051.40
₹2,064.40
+1.21%
12-May-25
₹1,998.00
₹2,039.80
+0.12%
09-May-25
₹1,977.10
₹2,037.40
+1.12%
08-May-25
₹2,078.80
₹2,014.80
-2.73%
07-May-25
₹2,025.10
₹2,071.40
+1.09%
06-May-25
₹2,055.00
₹2,049.00
-1.74%
05-May-25
₹2,070.00
₹2,085.30
+1.37%

Lupin Shareholding Pattern

Promoters (46.92%)

Mutual Funds (17.55%)

Retail and other (6.2%)

Foreign institutions-FII (21.46%)

Other domestic institutions (7.87%)

Promoters

Events

Corporate Actions

  • Dividend • ₹8/share

    Ex date 16 Jul 2024

    expand tab
  • Dividend • ₹4/share

    Ex date 14 Jul 2023

    expand tab

More

Stocks Similar to Lupin

PriceNo Sort
Change %No Sort
Abbott India₹30,430.00+₹105.00 (0.35%)
Alkem Laboratories₹5,143.00+₹16.00 (0.31%)
Aurobindo Pharma₹1,218.90-₹1.10 (-0.09%)
Biocon₹336.35-₹1.85 (-0.55%)
GlaxoSmithKline Pharma₹2,870.00-₹8.80 (-0.31%)
Laurus Labs₹611.50+₹5.55 (0.92%)
Torrent Pharmaceuticals₹3,234.20-₹10.70 (-0.33%)
Zydus Lifesciences₹903.95+₹0.45 (0.05%)

Popular Stocks

PriceNo Sort
Change %No Sort
HDFC Bank₹1,903.10-₹7.50 (-0.39%)
Infosys₹1,585.00-₹7.40 (-0.46%)
ITC₹427.75-₹1.35 (-0.31%)
JIO FIN SERVICES LTD₹268.00+₹0.50 (0.19%)
Reliance Industries₹1,420.90-₹3.50 (-0.25%)
State Bank of India₹800.60-₹0.10 (-0.01%)
Tata Motors₹703.65+₹4.70 (0.67%)
Tata Power₹397.60+₹0.65 (0.16%)
Tata Steel₹156.05+₹0.74 (0.48%)
Wipro₹252.95+₹0.01 (0.00%)

FAQs on Lupin

What is the share price of Lupin today?

chevron-up
Lupin share price is ₹ 2,086.30 as on May 15, 2025 | 09:25 IST.

What are the high & low share price of Lupin today?

chevron-up
Lupin share price hit a high of ₹ 2,118.90 and low of ₹ 2,063.80 as on May 15, 2025 | 09:25 IST.

What are the the 52-week high and low share prices of Lupin share on the NSE?

chevron-up
52-week high share Price of Lupin is ₹ 2,402.90 and Low Price is ₹ 1,493.30 as on May 15, 2025 | 09:25 IST.

What is the stock symbol of Lupin?

chevron-up
The stock symbol of Lupin is LUPIN.

Can I buy Lupin shares on Holidays?

chevron-up
No, shares of Lupin or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Lupin shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.